micro-community-banner
 
  • Saved

November 18, 2024
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC - PubMed

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37870973/

Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov...

Selpercatinib significantly improved progression-free survival compared to platinum-based chemotherapy with or without pembrolizumab in advanced RET fusion-positive NSCLC, with similar safety profiles (ClinicalTrials.gov: NCT04194944).

Profile Image
  • Saved

November 11, 2024
Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis - PubMed

Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37392903/

Comprehensive meta-analysis indicates a higher prevalence and incidence of BM in patients with certain targetable genomic alterations. This supports brain imaging at staging and follow-up, and the need for targeted...

The meta-analysis reveals increased brain metastasis prevalence and incidence in NSCLC patients with specific genomic alterations, highlighting the importance of brain imaging and brain-penetrant targeted therapies in managing these cases.

Profile Image
  • Saved

November 11, 2024
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers - PubMed

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38118420/

The US Food and Drug Administration (FDA) approval of the selective RET inhibitors selpercatinib and pralsetinib has led to a paradigm change in the treatment of RET-altered lung and thyroid...

The FDA approval of selective RET inhibitors selpercatinib and pralsetinib revolutionizes RET-altered cancer treatment, offering high response rates and manageable toxicity, with broad potential across various tumor types.

Profile Image
  • Saved

November 06, 2024
Background Image DesktopBackground Image Mobile

Personalized precision medicine is central to modern healthcare, and Organoids-on-a-Chip (OoCs) represent a groundbreaking innovation. This review discusses how OoCs enhance patient-specific treatment by utilizing organoids for precise disease modeling, drug screening, and therapeutic individualization. It highlights the fusion of organoid culture with microfluidic technology, emphasizing its potential to transform healthcare through genomic medicine and ethical frameworks, ultimately improving patient outcomes and redefining treatment approaches.

Read More

Profile Image
  • Saved

November 05, 2024
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC - PubMed

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37870973/

Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov...

Selpercatinib showed significantly longer progression-free survival and higher response rates than platinum-based chemotherapy (with/without pembrolizumab) in RET fusion-positive NSCLC, with CNS efficacy and consistent adverse events (NCT04194944).

Profile Image